CAS: 6054-98-4; Sodium 5,5'-(Diazene-1,2-Diyl)Bis(2-Hydroxybenzoate)

该化合物是一种化学化合物,主要用作治疗肺炎的药物,一种发炎性肠胃疾病,一种在结肠中转化成5-氨-氨-西里西酸(5-ASA),具有抗炎作用;该化合物是一种盐,其分子结构有两种5-ASA分子,由松松结菌连接;奥沙拉津钠通常以口服方式施用,以其相对较低的系统吸收作用而著称,这有助于最大限度地减少副作用;该化合物的特点是溶性,有利于其在胃肠道中的吸收;常见副作用可能包括胃肠扰动,如腹泻和腹部疼痛;由于其行动机制,据认为,阿沙拉津钠钠在保持高血糖结膜患者的再入方面是有效的;与任何药物一样,病人必须咨询保健专业人员,以便适当使用和可能与其他药物发生相互作用.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2013035307-A1
    优先权日:2010-01-26
    标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
    发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
    权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
    摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

    专利号:US-11857778-B2
    优先权日:2018-01-17
    标 题:Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation
    发明人:HAMNER SAMUEL RICHARD; ROSS ERIKA KRISTINE; ROSENBLUTH KATHRYN H
    权利人:CALA HEALTH INC
    摘要:Systems and methods for treating symptoms of an inflammatory gastrointestinal disease in a patient with transcutaneous stimulation of a peripheral nerve are disclosed. The method can include any number of positioning a first peripheral nerve effector on the patient's skin to stimulate the peripheral nerve of the patient, delivering a first electrical nerve stimulation signal transcutaneously to the peripheral nerve through the first peripheral nerve effector, and modifying at least one brain or spinal cord autonomic feedback loop relating to release of neurotransmitters from the autonomic nervous system that modulate synthesis of inflammatory biomarkers and reduce inflammation relating to the inflammatory gastrointestinal disease.

    专利号:WO-2023096715-A9
    优先权日:2021-10-22
    标 题:Immunomodulatory glycosphingolipids and methods of use thereof
    发明人:KASPER DENNIS; OH SUNGWHAN
    权利人:HARVARD COLLEGE
    摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

    专利号:US-2022125838-A1
    优先权日:2019-02-11
    标题 :Immunomodulatory glycosphingolipids and methods of use thereof
    发明人:OH SUNGWHAN; KASPER DENNIS L; SONG HEEBUM; PARK SEUNG BUM
    权利人:HARVARD COLLEGE; SEOUL NAT UNIV R&DB FOUNDATION
    摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

    专利号:US-9907753-B2
    优先权日:2010-03-19
    标 题 :Lipid vesicle compositions and methods of use
    发明人:IRVINE DARRELL J; MOON JAEHYUN
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

    专利号:CN-101627049-B
    优先权日:2006-11-10
    标题 :Synthesis of phthalamides
    山东天铭医药集团有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.sdpysh.com
    电话: 0531-89702887/0531-88993893👤
    📞山东天铭医药集团有限公司 ⚠️参考联系方式

    销售电话:0531-89702887/0531-88993893
    邮箱:sales@sdsihuanpharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    辽宁诺维诺制药股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.lnnvn.com
    电话: 024-47509666👤
    📞辽宁诺维诺制药股份有限公司 ⚠️参考联系方式

    销售电话:024-47509666
    邮箱:office@lnnvn.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Niu Y, Yang P, Li H, Li Q, Lin H, Gao L, Li L. Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals. Biol Pharm Bull. 2020 Nov 1;43(11):1653-1659. doi: 10.1248/bpb.b20-00362. Epub 2020 Aug 28. 135(3):114-120. doi: 10.1016/j.jphs.2017.10.007. Epub 2017 Oct 31.
    1008:1-10. doi: 10.1016/j.jchromb.2015.11.001. Epub 2015 Nov 4. 70(6):709-17. doi: 10.1007/s00228-014-1660-7. Epub 2014 Mar 11.
    5: Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005 Jan 6;57(2):281-302. doi: 10.1016/j.addr.2004.08.008. 10(10):1513-20. doi: 10.3748/wjg.v10.i10.1513.

    合成参考文献


    参考文献:10.1186/s12876-021-01887-2
    摘要:Li S, Yin Y, Xiao D, Zou Y. Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients. BMC Gastroenterology. 2021 Aug 04;21(1):314. doi: 10.1186/s12876-021-01887-2.
    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知